CD8A and neoplasm: TNBCvax provides a promising immunotherapeutic strategy capable of orchestrating a coordinated antitumor immune response, improving both CD8+ cytotoxicity and CD4+-mediated immune modulation while alleviating immunosuppressive features within the tumor microenvironment.